See more : Ambar Protein Industries Limited (AMBARPIL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of SIGA Technologies, Inc. (SIGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SIGA Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Shanghai Yahong Moulding Co., Ltd. (603159.SS) Income Statement Analysis – Financial Results
- The Stanley Gibbons Group plc (SGI.L) Income Statement Analysis – Financial Results
- JFrog Ltd. (FROG) Income Statement Analysis – Financial Results
- Solera National Bancorp, Inc. (SLRK) Income Statement Analysis – Financial Results
- A.P. Møller – Mærsk A/S (AMKAF) Income Statement Analysis – Financial Results
SIGA Technologies, Inc. (SIGA)
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.92M | 110.78M | 133.67M | 124.96M | 26.74M | 477.05M | 12.27M | 14.99M | 8.18M | 3.14M | 5.52M | 8.97M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 483.12K | 500.00K | 500.00K | 700.00K | 100.00K |
| Cost of Revenue | 17.83M | 32.96M | 26.54M | 25.74M | 15.09M | 108.29M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -945.40K | -400.00K | -200.00K | 0.00 | 0.00 |
| Gross Profit | 122.09M | 77.82M | 107.13M | 99.22M | 11.66M | 368.77M | -4.41M | -4.72M | -4.95M | -7.69M | -8.34M | -9.24M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 1.43M | 900.00K | 700.00K | 700.00K | 100.00K |
| Gross Profit Ratio | 87.26% | 70.25% | 80.14% | 79.40% | 43.59% | 77.30% | -35.95% | -31.51% | -60.60% | -244.93% | -151.06% | -103.02% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 295.69% | 180.00% | 140.00% | 100.00% | 100.00% |
| Research & Development | 16.43M | 24.11M | 9.94M | 10.94M | 13.30M | 13.02M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 18.37M | 22.66M | 17.42M | 11.61M | 9.94M | 9.15M | 8.30M | 4.17M | 2.94M | 1.77M | 1.73M | 2.61M | 1.70M | 2.90M | 900.00K | 700.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.88M | 12.30M | 13.71M | 24.99M | 200.99M | 1.42M | 1.88M | 25.74M | 1.15M | 734.17K | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.41M | -188.47M | 11.82M | 9.53M | 0.00 | 8.13M | 7.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.04M | 35.12M | 17.32M | 14.00M | 13.25M | 12.88M | 12.30M | 13.71M | 10.58M | 12.52M | 13.24M | 11.41M | 25.74M | 9.28M | 8.27M | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 800.00K |
| Other Expenses | 0.00 | -24.11M | 710.15K | 719.14K | 726.11K | 78.94M | 16.79K | -1.66M | 42.20K | 1.07K | 1.50K | 522.00 | 0.00 | 0.00 | 4.35B | 0.00 | 0.00 | 0.00 | 0.00 | 2.12M | 136.75K | 0.00 | 117.26K | 945.40K | 400.00K | 200.00K | 100.00K | 0.00 |
| Operating Expenses | 22.04M | 35.12M | 18.03M | 14.72M | 13.98M | 13.67M | 13.21M | 14.62M | 11.59M | 13.51M | 14.67M | 13.29M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 8.51M | 4.40M | 5.90M | 3.00M | 1.50M |
| Cost & Expenses | 56.30M | 68.08M | 44.58M | 40.46M | 29.06M | 121.95M | 29.89M | 34.33M | 24.72M | 24.34M | 28.52M | 31.51M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 7.57M | 4.00M | 5.70M | 3.00M | 1.50M |
| Interest Income | 4.16M | 0.00 | 101.17K | 2.48M | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.26K | 34.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.02M | 15.77M | 15.48M | 14.76M | 14.06M | 266.73K | 455.81K | 1.21M | 172.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.68K | 550.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 538.29K | 517.64K | 522.37K | 529.81K | 527.00K | 69.63K | 132.19K | 174.28K | 247.36K | 351.56K | 463.14K | 419.36K | 568.29K | 625.34K | 475.09K | 459.88K | 1.25M | 1.56M | 1.33M | 1.05M | 739.56K | 317.03K | 556.86K | 945.40K | 400.00K | 200.00K | 100.00K | 900.00K |
| EBITDA | 84.16M | 43.22M | 89.62M | 85.03M | 1.03M | 355.17M | -23.44M | -25.45M | -38.48M | -211.13M | -23.13M | -21.78M | -21.87M | -27.57M | -11.40M | -8.28M | -6.21M | -5.25M | -1.20M | -8.32M | -4.56M | -3.05M | -2.70M | -6.14M | -3.08M | -5.00M | -1.80M | -500.00K |
| EBITDA Ratio | 60.15% | 39.48% | 67.12% | 68.47% | 3.84% | 91.00% | -142.43% | -139.01% | -198.83% | -664.03% | -408.36% | -246.53% | -312.41% | 17.57% | -41.01% | -104.33% | -120.00% | -29.85% | -17.10% | -283.50% | -603.84% | -884.91% | -199.45% | -1,238.31% | -620.00% | -740.00% | -314.29% | -500.00% |
| Operating Income | 83.62M | 42.70M | 89.09M | 84.50M | 500.09K | 355.10M | -18.85M | -31.01M | -30.95M | -209.67M | -23.52M | -22.54M | -31.38M | -12.72M | -11.88M | -8.74M | -7.46M | -6.81M | -2.53M | -9.45M | -5.29M | -3.37M | -3.26M | -7.08M | -3.50M | -5.20M | -2.30M | -1.40M |
| Operating Income Ratio | 59.76% | 38.55% | 66.65% | 67.62% | 1.87% | 74.44% | -153.63% | -206.94% | -378.59% | -6,677.64% | -426.07% | -251.21% | -246.60% | -66.21% | -86.01% | -108.32% | -111.41% | -93.84% | -29.87% | -513.72% | -723.60% | -976.95% | -281.31% | -1,466.21% | -700.00% | -1,040.00% | -328.57% | -1,400.00% |
| Total Other Income/Expenses | 4.16M | 1.43M | 218.94K | -10.99M | -7.86M | 56.54M | -19.48M | -8.67M | -8.04M | -2.27M | -1.28M | 632.05K | 8.94M | -37.45M | -5.74M | 137.53K | 1.82M | -3.09M | 244.79K | 74.97K | -136.75K | 0.00 | -392.37K | -155.59K | 0.00 | -1.30M | 0.00 | -900.00K |
| Income Before Tax | 87.78M | 44.13M | 89.31M | 73.51M | -10.18M | 411.64M | -38.33M | -39.68M | -38.99M | -211.93M | -24.80M | -22.37M | -22.44M | -19.40M | -17.62B | -8.60M | -5.64M | -9.90M | -2.29M | -12.06M | -5.43M | 0.00 | -3.65M | -7.24M | 0.00 | -6.50M | 0.00 | -2.30M |
| Income Before Tax Ratio | 62.73% | 39.84% | 66.81% | 58.83% | -38.06% | 86.29% | -312.41% | -264.78% | -476.88% | -6,749.87% | -449.26% | -249.39% | -176.31% | -100.96% | -127,556.62% | -106.62% | -84.17% | -136.39% | -26.99% | -655.72% | -742.29% | 0.00% | -315.15% | -1,498.41% | 0.00% | -1,300.00% | 0.00% | -2,300.00% |
| Income Tax Expense | 19.71M | 10.23M | 19.86M | 17.17M | -2.94M | -10.17M | -2.09M | 13.88K | 461.98K | 53.53M | -7.62M | -7.84M | -36.03M | 15.47M | 5.74M | -137.53K | -1.82M | 3.09M | -244.79K | 493.36K | -18.26K | -34.06K | 467.79K | 706.06K | 100.00K | 1.40M | -100.00K | 0.00 |
| Net Income | 68.07M | 33.90M | 69.45M | 56.34M | -7.24M | 421.81M | -36.24M | -39.70M | -39.45M | -265.46M | -17.18M | -14.53M | 13.59M | -28.20M | -17.62M | -8.60M | -5.64M | -9.90M | -2.29M | -9.37M | -5.28M | -3.33M | -3.73M | -7.79M | -3.60M | -6.60M | -2.20M | -2.30M |
| Net Income Ratio | 48.65% | 30.61% | 51.96% | 45.09% | -27.08% | 88.42% | -295.34% | -264.87% | -482.53% | -8,454.68% | -311.22% | -161.95% | 106.82% | -146.73% | -127.56% | -106.62% | -84.17% | -136.39% | -26.99% | -509.65% | -721.11% | -967.06% | -321.66% | -1,612.35% | -720.00% | -1,320.00% | -314.29% | -2,300.00% |
| EPS | 0.95 | 0.46 | 0.92 | 0.71 | -0.09 | 5.28 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.57 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| EPS Diluted | 0.95 | 0.46 | 0.91 | 0.71 | -0.09 | 5.10 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.09 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| Weighted Avg Shares Out | 71.36M | 72.93M | 75.32M | 79.26M | 81.03M | 79.92M | 78.77M | 57.19M | 53.78M | 53.41M | 52.05M | 51.64M | 50.93M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.58M | 6.54M | 3.89M | 3.07M |
| Weighted Avg Shares Out (Dil) | 71.68M | 73.55M | 76.40M | 79.44M | 82.18M | 82.71M | 78.87M | 57.19M | 53.78M | 53.42M | 52.37M | 51.64M | 54.06M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.59M | 6.55M | 3.89M | 3.07M |
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March...
SIGA Declares Special Cash Dividend of $0.60 Per Share
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024....
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective...
SIGA Technologies: Impressive Net Sales Guidance, FDA Approval, And Cheap
SIGA Technologies delivered impressive net sales expectations for Q4 and is working to expand its treatment of human smallpox in new jurisdictions. The company has regulatory approvals for its oral antiviral drug Tpoxx and is exploring expanding its FDA label...
SIGA Technologies, Inc. (SIGA) Q3 2023 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Phillip Louis Gomez - Chief Executive Officer Dennis Hruby - Executive Vice President and Chief Scientific Officer Jay Varma - Executive Vice...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023....
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission's DG HERA (Health Emergency Preparedness and Response Authority)...
Top 5 High-Flying Nasdaq Stocks Defying Index's Recent Turmoil
We have narrowed our search to five Nasdaq Composite-listed stocks that have popped more than 10% in the past month. These are: VIRC, GIII, SIGA, DUOL, LTRX.
Source: https://incomestatements.info
Category: Stock Reports